Trade
Sun Pharmaceutical Industries share price
Moderate risk
You have to be logged in to add this to Watchlist.- ₹1,935.25(-0.19%)July 10, 2026 15:49:57 PM IST
- NSE
- BSE
- Vol : 1.52 M (NSE + BSE)Last 20 day avg : 2.17 M
Sun Pharmaceutical Industries is trading -0.19% lower at Rs 1,935.25 as compared to its last closing price. Sun Pharmaceutical Industries has been trading in the price range of 1,953.75 & 1,926.05. Sun Pharmaceutical Industries has given 12.73% in this year & 3.62% in the last 5 days. Sun Pharmaceutical Industries has TTM P/E ratio 38.00 as compared to the sector P/E of 26.80.There are 33 analysts who have initiated coverage on Sun Pharmaceutical Industries. There are 10 analysts who have given it a strong buy rating & 19 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 2,714.03 Crores in its last quarter.Listed peers of Sun Pharmaceutical Industries include Divi's Laboratories (0.31%), Dr Reddy's Laboratories (-1.91%), Cipla (-0.20%).The Mutual Fund holding in Sun Pharmaceutical Industries was at 11.96% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Sun Pharmaceutical Industries was at 15.94% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 10, 2026, 05:43 PM UTC
- BetaLow volatility0.76Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.06The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.83Annual dividends as a percentage of the stock price.
- P/BLower than historical values5.57The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values40.52Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation4.31The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Sun Pharmaceutical Industries News
Sun Pharmaceutical Industries Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Divi's Laboratories | 6,832.30 | 0.31 | 1,81,268.32 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | 1,245.50 | -1.91 | 1,03,954.01 | 18.63 | 3.14 | 0.63 | 2.34 |
| Cipla | 1,438.75 | -0.20 | 1,16,228.75 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | 4,895.20 | -0.03 | 1,65,669.16 | 67.32 | 17.1 | 0.83 | 17.62 |
| Lupin | 2,496.90 | -0.24 | 1,14,082.07 | 28.78 | 5.59 | 0.57 | 11.80 |
Mutual Fund Ownership
View allSun Pharmaceutical Industries Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-01-31 | Quarterly Results & Interim Dividend |
| 2025-11-05 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
| 2025-05-22 | Audited Results & Final Dividend |
About the company Sun Pharmaceutical Industries
- IndustryBiotechnology & Drugs
- ISININE044A01036
- BSE Code524715
- NSE CodeSUNPHARMA
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Share Price FAQs
Sun Pharmaceutical Industries is trading at 1935.25 as on Fri Jul 10 2026 10:19:57. This is -0.19% lower as compared to its previous closing price of 1938.85.
The market capitalization of Sun Pharmaceutical Industries is 464320.36 Cr as on Fri Jul 10 2026 10:19:57.
The average broker rating on Sun Pharmaceutical Industries is Buy. The breakup of analyst rating is given below -
- 10 analysts have given a strong buy rating
- 19 analysts have given a buy rating
- 1 analysts have given a hold rating
- 2 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Sun Pharmaceutical Industries is 1952.10 whereas the 52 wk low is 1547.25
Sun Pharmaceutical Industries can be analyzed on the following key metrics -
- TTM P/E: 38.00
- Sector P/E: 26.80
- Dividend Yield: 0.83%
- D/E ratio: 0.06
Sun Pharmaceutical Industries reported a net profit of 11479.42 Cr in 2026.
The Mutual Fund Shareholding was 11.96% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Sun Pharmaceutical Industries QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.